The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 28, Issue 3, 2008, Pages 340-342

  Li, Xiaomao ^a,b   Xiao, Lan ^b   Yang, Yuebo ^b   Shen, Huimin ^b   Zeng, Haitao ^b   Wang, Zehua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Endometrial carcinoma; HEC 1A; Ishikawa; Mammalian target of rapamycin; PTEN

Indexed keywords

EIF4EBP1 PROTEIN, HUMAN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN KINASE; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CARCINOMA; CONFOCAL MICROSCOPY; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROSCOPY, CONFOCAL; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION;

EID: 45749095886     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-008-0325-0     Document Type: Article

References (10)

1. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted anti-tumour therapy. Cell Mol Biol Lett, 2005,10:479-498
2. Xu G, Zhang W, Bertram P et al. Pharmacogenomic profiling of the PI3K/PTEN/AKT/mTOR pathway in common human tumor. Int J Oncol, 2004,24(4):901-908
3. Sahin F, Kannangai R, Adegbola O et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res, 2004,10:8421-8425
4. Ito D, Fujimoto K, Mori T et al. In vivo antitumor effect of the mTOR inhibitor CCI2779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer, 2006,118:2337-2343
5. Altomare D A, You H, Xiao G H et al. Human and mouse mesotheliomas exhibit elevated activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene, 2005,24(40):6080-6089
6. Tolcher A. Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor. J Urol, 2004,171(2 Pt 2):41-44
7. Asano T, Yao Y, Zhu J et al. The rapamycin anolog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun, 2005,331:295-302
8. Atkins M B, Hidalgo M, Stadler W M et al. Randomized phase II study of multiple does levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomas. J Clin Oncol, 2004,22:909-918
9. Cantley L C, Neel B G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci, USA, 1999,96(8):4240-4245
10. Bakiewicz A, Gozdzik J, Sporny S. Pten gene expression in the endometrial mucosa. Ginekol Pol, 2006,77(4):323-329